(19) (KR)
(12) (A)

(11) 10-2010-0040539
(43) 2010 04 20

(51) Int. Cl.
A61K 36/68 (2006.01) *A61P 35/00* (2006.01)
(21) 10-2008-0099709
(22) 2008 10 10
2008 10 10

(71)
100
(72)
492-39
1 53-3 B-101
( )
(74)


: 4

(54)

(57)

, , 85%aq. MeOH, n- n-BuOH , .

- 1



(72)

107

4

111-2401

829-39

1

1 ;

1 , 2 ;

1 2 , n- , 85%aq. MeOH, n-BuOH H_2O

;

,

.

2

1 .

3

1

.

4

3 , n- , 85%aq. MeOH n-BuOH

.

[0001] ,

, n- , 85%aq. MeOH, n-BuOH H_2O

.

[0002] , ,

.

.

, , , , ,

, , , .

[0003] (halophyte) ,

, , , , ,

, , .

.

.

, .

[0004] (*Limonium tetragonum*) [*Limonium tetragonum*(*Thumb*) A.A. Bullock] 2
, Na , , .
, ,
. ,
.

[0005]
,
AGS HT-29
.

[0006] (*Limonium tetragonum*)
.

[0007] ,
, AGS HT-29 .

[0008] .

[0009] , 1 ;
1 , 2 ;
1 2 , n- , 85%aq. MeOH, n-BuOH H_2O
; , .

[0010] .

[0011]
.

[0012] n- , 85%aq. MeOH n-BuOH ,
, .

[0013] , " "
( )
.

[0014]
. 200 μg/mL

66% 71% , 60% 84% .

, AGS HT-29 .

[0015] , . 85%aq. MeOH , H_2O 50% . AGS 200 μg/mL 85%aq. MeOH, n- n-BuOH 80% , HT-29 85%aq. MeOH n- , . .

[0016] , 85%aq. MeOH, n- n-BuOH , .

[0017] . .

[0018] **1 :**

[0019] (*Limonium tetragonum*) 2003 5 , -25 .

[0020] (*Linonium tetragonum*) , (CH_2Cl_2) 24 . 2 . 40 (EYELA JAPAN, N-N) , (MeOH) . 123.43 g n- , 85% MeOH, n-BuOH H_2O , , . n- , 85%aq. MeOH, n-BuOH H_2O 10.14 g, 5.46 g, 5.89 g 101.94 g (1). (DMSO) .

[0021] **1 :**

[0022] RPMI 1640, (FBS) 0.05% -0.002% EDTA 100 units/mL - (PBS) (GIBCO; USA) , .

[0023] AGS (AGS human gastric cancer cell) HT-29 (HT-29 human colon cancer cell) ( ) . AGS HT-29 100 units/mL - 10% FBS PRMI 1640 37 , 5% CO_2 (Forma Scientific, Japan) . 2-3 , 6-7 PBS , 0.05% -0.02% EDTA

, 75 mL
10 mL , 6-7 .

[0024] **2 : MTT**

[0025] MTT MTT[3-(4,5-
-2-)-2,5-]
,
.

[0026] $2X10^4$ cells/mL 96 37 , 5% CO_2 24
, , 180 μL 20 μL , 37 , 5%
CO_2 48 . (PBS) 20 μL . 48
5 mg/mL MTT 20 μL 4
. DMSO ELISA (Bio-TeK instruments, USA)
540 nm (%) .

[0027] -

[0028] (%) = ---------- X 100

[0029]

[0030] , (ANOVA) $p<0.05$
, ± .
(v8.2 SAS Institute Inc., NC, USA) .

[0031] **3 :**

[0032] 1 AGS HT-29
. 5, 10, 50, 100 200 μg/mL
(2),
. 100 μg/mL
, 43% 63% , 200 μg/mL
66% 71% .

.

[0033] HT-19
(3). 10 μg/mL
. 200 μg/mL
84% .
60% ,
. 200 μg/mL
AGS HT-29 .

[0034] **4 :**

[0035]
, .
.

[0036] AGS
4 . 5, 10, 100 200 μg/mL , 85%aq. MeOH 25,
30, 70, 75 79% , n- 23, 23, 38, 67 78%
. n-BuOH 21, 23, 31, 61 68%
. H_2O ,
, 50%
.

[0037] HT-29
(5). 5, 10, 100 200 μg/mL
, 85%aq. MeOH
, H_2O 50%
. , 5, 10, 100 200 μg/mL , 85%aq. MeOH
28, 35, 57, 89 95% , 100 μg/mL
. n-BuOH 23, 25, 41, 49 70% , H_2O
15, 20, 30, 30 46% . n-
24, 29, 42 61 93% 85%aq. MeOH
.

[0038] , .
AGS , 200 μg/mL 80%
85%aq. MeOH, n- n-BuOH . HT-29 85%aq.
MeOH n- ,
.

[0039] ,
. , , ,
,
.

[0040] .
.
.
,
.

[0041] .
85%aq. MeOH, n- n-BuOH .
,
. ,
, .

[0042] 1 .


[0043] 2 AGS .

[0044] 3 HT-29 .


[0045] 4 AGS .

[0046] 5 HT-29 .


1




2




3


MeOH ext.
CH_2Cl_2 ext.
Cell Viability (%)
Con 200 100 50 10 5 200 100 50 10 5
Concentration (㎍/㎖)

4


H_2O fr.
n-BuOH fr.
85% aq.MeOH fr.
n-hexane fr.
Cell Viability (%)
Con 200 100 50 10 5
Concentration (㎍/㎖)

5


H2O fr.
n-BuOH fr.
85% aq.MeOH fr.
n-hexane fr.
Cell Viability (%)
Con 200 100 50 10 5
Concentration (㎍/㎖)